



BANDARAM PHARMA PACKTECH LIMITED

CIN:L93090KA1993PLC159827

To,

Date: 22.07.2022

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 22.07.2022

Ref: Company's Letter dated 16.07.2022

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Bandaram Pharma Packtech Limited (formerly known as Shiva Medicare Limited)** at its meeting held on Friday, the 22nd day of July 2022 at 3.00 P.M. at the registered office of the Company situated at 601, 5th Floor, Oxford Towers, Opp to Leela Palace Hotel, Old Airport Road, Kodihalli Bangalore - 560008, Karnataka, approved the following items of business:

1. Unaudited financial results (both standalone and consolidated) for the quarter ended 30.06.2022. **(Enclosed)**
2. Limited Review Report (both standalone and consolidated) as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the Quarter ended 30.06.2022. **(Enclosed)**

This is for the information and records of the Exchange, please.

The meeting concluded at 5:00 p.m.

Thanking you.

For Bandaram Pharma Packtech Limited
(formerly known as Shiva Medicare Limited)

B. Mumuksham Reddy
Managing Director
DIN: 09487708

Encl. as above



BANDARAM PHARMA PACKTECH LIMITED

CIN:L93090KA1993PLC159827

BANDARAM PHARMA PACKTECH LIMITED (Formerly Known as Shiva Medicare Limited) CIN: L93090KA1993PLC159827 Regd. Office: 601, 5th Floor, Oxford Towers, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore - 560008.												
Statement of Unaudited Results for the Quarter Ended and Three Months Ended 30.06.2022 (Amount: Rs. in lakhs)												
S.No.	Particulars	START ALONE					CONSOLIDATED					
		For the Quarter ended		Three Months ended		Previous Year	For the Quarter ended		Three Months ended		Previous Year	
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	30.06.2022 (Unaudited)	30.06.2021 (Unaudited)	31.03.2022 2 (Audited)	30.06.2022 2 (Unaudited)	31.03.2022 1 (Audited)	30.06.2022 2 (Unaudited)	30.06.2022 1 (Unaudited)	31.03.2022 2 (Audited)
I.	Revenue from Operations	-	-	-	-	-	-	90.62	-	90.62	-	-
II.	Other Income	-	-	-	-	-	-	-	-	-	-	-
III.	Total Income (I+II)	-	-	-	-	-	-	90.62	-	90.62	-	-
IV.	Expenses	-	-	-	-	-	-	-	-	-	-	-
	(a) Cost of Materials consumed	-	-	-	-	-	-	86.05	-	86.05	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-	-	-	-	-	-
	(c) Changes in inventories of finished goods	-	-	-	-	-	-	14.83	-	14.83	-	-
	(d) Employee benefits expenses	0.50	-	-	0.50	-	-	7.70	-	7.70	-	-
	(e) Finance Cost	-	0.01	-	-	0.01	0.01	5.97	0.01	5.97	-	0.01
	(f) Depreciation and amortisation	-	-	-	-	-	-	5.32	-	5.32	-	-
	(h) Other expenses	11.94	1.00	-	11.94	1.00	17.10	1.00	17.10	1.00	-	1.00
	Total Expenses	12.44	1.01	-	12.44	1.01	107.31	1.01	-	107.31	-	1.01
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	(12.44)	(1.01)	-	(12.44)	-	(1.01)	(16.69)	(1.01)	(16.69)	-	(1.01)
VI.	Exceptional items	-	-	-	-	-	-	-	-	-	-	-
VII.	Profit / (Loss) from before tax (V-VI)	(12.44)	(1.01)	-	(12.44)	-	(1.01)	(16.69)	(1.01)	(16.69)	-	(1.01)
VIII.	Tax expense	-	-	-	-	-	-	-	-	-	-	-
	Current Tax	-	-	-	-	-	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-	-	-	-	-	-
IX.	Net Profit / (Loss) for the period from Continuing operations (VII-VIII)	(12.44)	(1.01)	-	(12.44)	-	(1.01)	(16.69)	(1.01)	(16.69)	-	(1.01)
X.	Profit / (Loss) from discontinuing operations	-	-	-	-	-	-	-	-	-	-	-
XI.	Profit / (Loss) from discontinuing operations after tax	-	-	-	-	-	-	-	-	-	-	-
XII.	Profit / (Loss) for the Period (IX+XII)	(12.44)	(1.01)	-	(12.44)	-	(1.01)	(16.69)	(1.01)	(16.69)	-	(1.01)
XIII.	Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-
A.	(i) Items that will not be recycled to profit or loss	-	-	-	-	-	-	-	-	-	-	-
	(a) Others (gratuity and leave encashment excess provision reversal)	-	-	-	-	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-
B.	(i) Items that may be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-
	(ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-
	Total Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-
XV.	Total Comprehensive Income for the	(12.44)	(1.01)	-	(12.44)	-	(1.01)	(16.69)	(1.01)	(16.69)	-	(1.01)
XVI.	Earnings Per Equity Share of face value of Rs.10/- each (for Continuing)	-	-	-	-	-	-	-	-	-	-	-
	1) Basic	(0.41)	(0.03)	-	(0.41)	-	(0.03)	(0.56)	(0.03)	(0.56)	-	(0.03)
	2) Diluted	(0.41)	(0.03)	-	(0.41)	-	(0.03)	(0.56)	(0.03)	(0.56)	-	(0.03)
XVII.	Earnings Per Equity Share of face value of Rs.10/- each (for Discontinuing)	-	-	-	-	-	-	-	-	-	-	-
	1) Basic	(0.41)	(0.03)	-	(0.41)	-	(0.03)	(0.56)	(0.03)	(0.56)	-	(0.03)
	2) Diluted	(0.41)	(0.03)	-	(0.41)	-	(0.03)	(0.56)	(0.03)	(0.56)	-	(0.03)
XVIII.	Earnings Per Equity Share of face value of Rs.10/- each (for Continued and Discontinuing operations)	-	-	-	-	-	-	-	-	-	-	-
	1) Basic	(0.41)	(0.03)	-	(0.41)	-	(0.03)	(0.56)	(0.03)	(0.56)	-	(0.03)
	2) Diluted	(0.41)	(0.03)	-	(0.41)	-	(0.03)	(0.56)	(0.03)	(0.56)	-	(0.03)
XIX.	Paid-up equity share capital (Face Value of Rs. 10/- per share)	300.00	300.00	227.70	300.00	227.70	300.00	300.00	227.70	300.00	227.70	300.00

Notes:

- In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of the Companies Act, 2013, the above Financial Results have been prepared. The same is reviewed by the Statutory Auditors of Company and recommended by the Audit Committee and subsequently approved by the Board of Directors of Company at their meeting held on 22-07-2022.
- The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS-34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting pronouncements generally accepted in India.
- The figures of the previous year/periods have been re-grouped/re-classified, wherever necessary, for the purpose of comparison with the current year/period figures.
- The Company has no business operations during the quarter ending 30th June, 2022. Hence, segmentwise report as per Ind AS-108, is not applicable.
- The Company has acquired 55% shareholding in M/s. VSR Paper and Packaging Ltd., Hyderabad on 26-04-2022. Accordingly, this subsidiary company's quarterly results for the period ending 30th June, 2022, have been disclosed in this Financial Statements.
- The above Financial Results are also available on the company's website www.bandaram.com

Place : Bangalore
Date : 22-06-2022

For and on Behalf of the Board of Directors
Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)

M. Munirathnam Reddy
Managing Director
DIN: 09482708

Regd. & Corporate Office: Oxford Towers, Unit No. 601, 5th floor, Opp. to
Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore-560008
Ph No.: 9900002025 E-mail: info.bandaram@gmail.com



M M REDDY & CO.,
Chartered Accountants

Phone: 040 - 23418836

40272617

Mobile: 9848271555

M M R Lion Corp, 4th Floor, HSR Eden, Beside Cream Stone, Road No. 2, Banjara Hills, Hyderabad – 500034.TS. E-mail: mmreddyandco@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors,
BANDARAM PHARMA PACKTECH LIMITED

We have reviewed the accompanying statement of Un-audited Financial Results of **BANDARAM PHARMA PACKTECH LIMITED (formerly known as Shiva Medicare Limited)** for the quarter ended **30th June, 2022** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.


The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M M REDDY & CO.,
Chartered Accountants
Firm Regn No 010371S

M Madhusudhana Reddy
Partner
Membership No 213077
UDIN: 22213077ANLFWH6751





M M REDDY & CO.,
Chartered Accountants

Phone: 040 - 23418836

40272617

Mobile: 9848271555

M M R Lion Corp, 4th Floor, HSR Eden, Beside Cream Stone, Road No. 2, Banjara Hills, Hyderabad - 500034.TS. E-mail: mmreddyandco@gmail.com


Independent Auditor's Review Report on Interim Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of
M/s. BANDARAM PHARMA PACKTECH LIMITED

We have reviewed the quarterly Consolidated Unaudited Financial Results of **BANDARAM PHARMA PACKTECH LIMITED (formerly known as Shiva Medicare Limited)** ("The Company") and its subsidiaries (Collectively referred to as Group) for the quarter ended 30th June, 2022 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

These quarterly consolidated financial results as well have been prepared on the basis of the consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these Consolidated financial results based on our audit of such Consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our review of the Statement in accordance with the standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Attention is drawn to the statement which states that the Consolidated figures for the Corresponding quarters ended June 30, 2019 and March 31, 2020 as reported in the accompanying Statement have been approved by the Parent's Board of Directors, but have not been subjected to review.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

We did not review the interim financial information of Subsidiary company which are included in the consolidated quarterly unaudited financial results, whose consolidated interim financial information reflects, total revenues of VSR Paper and Packaging Limited is Rs. 90.62 Lakhs for the quarter ended 30th June, 2022, total net Loss of VSR Paper and Packaging Limited is Rs. 4.25 Lakhs and total comprehensive income of VSR Paper and Packaging Limited is Rs. 4.25 Lakhs for the quarter ended June 30, 2022. These interim financial information has been reviewed by other Auditors whose reports have been furnished to us by management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, based solely on the reports of the other auditors.


In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

- I. Include the quarterly financial results of the following entities: -
 - a) VSR Paper and Packaging Limited (Holding 55%)
- II. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard;

For M M REDDY & CO.

Chartered Accountants

Firm Registration No.0103718


M. Madhusudhana Reddy
Partner

Membership No.213077

UDIN: 22213077ANLGGD6192



Place: Hyderabad,
Date: 22-07-2022